Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 2/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | STS | P08842 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11209381 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL351004 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL11212923 | 0.92 | ESR1 (0.67) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL8519476 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL11481676 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL10349596 | 0.86 | MAPT (0.68) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL7518036 | 0.86 | MAPT (0.63) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL10349471 | 0.84 | MAPT (0.56) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL11213753 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP3A4MAPTTP53ESR1 | |
| SCHEMBL11875916 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP3A4MAPTTP53ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060153905-A1 | Transdermal pharmaceutical formulation for minimizing skin residues | ANTARES PHARMA, INC. | 2006-07-13 | — | — | US | claimed |
| EP-1670433-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES | Antares Pharma IPL AG (CH) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039531-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES | ANTARES PHARMA IPL AG (CH) | 2005-05-06 | — | — | WO | claimed |
| EP-1443939-A1 | COMPOSITIONS FOR TREATMENT OF POSTMENOPAUSAL FEMALE SEXUAL DYSFUNCTION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | claimed |
| EP-1329225-A2 | Transdermal device containing polyvinylpyrrolidone as solubility enhancer | NOVEN PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030130244-A1 | Compositions for treatment of postmenopausal female sexual dysfunction | PHARMACIA CORPORATION | 2003-07-10 | — | — | US | claimed |
| WO-2003039553-A1 | COMPOSITIONS FOR TREATMENT OF POSTMENOPAUSAL FEMALE SEXUAL DYSFUNCTION | PHARMACIA CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | claimed |
| US-20250032509-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-12144817-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| EP-0675723-A1 | BISPHOSPHONATE/ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS | MERCK & CO. INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1994014455-A1 | BISPHOSPHONATE/ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | SMN1; SMN2 1037/4885CYP3A4 1499/4885MAPT 954/4885 |
| US-20250032509-A1 | Testosterone Ester Triglyceride Formulations | SHBG, NR5A1, HSD17B11 | SMN1; SMN2 2028/4885CYP3A4 118/4885MAPT 2165/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | SMN1; SMN2 224/4885CYP3A4 212/4885MAPT 845/4885 |
| US-12144817-B2 | Testosterone ester triglyceride formulations | SHBG, NR5A1, HSD17B11 | SMN1; SMN2 2028/4885CYP3A4 118/4885MAPT 2165/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | SMN1; SMN2 1157/4885CYP3A4 1393/4885MAPT 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.